Aveanna Healthcare stock rating upgraded by Raymond James on improved outlook

Raymond James upgraded Aveanna Healthcare Holdings (NASDAQ: AVAH) to Outperform with a $9.00 price target, citing the company's Q2 2025 results which significantly exceeded both revenue and EPS consensus forecasts. This upgrade, amid AVAH's recent 61% stock gain, is driven by expectations of substantial deleveraging by 2027, projected valuation upside, and potential debt refinancing opportunities stemming from an improved credit profile.

Analysis

Raymond James has upgraded Aveanna Healthcare Holdings (AVAH) to Outperform with a $9.00 price target, a significant move following the stock's 61% gain in the past week. The upgrade is directly tied to the company's second-quarter 2025 financial results, which substantially surpassed expectations. Aveanna reported a Q2 EPS of $0.18, a 350% surprise over the $0.04 consensus, on revenue of $590 million, which beat projections by 10.43%. This strong performance underpins Raymond James's bullish thesis, which is built on three key pillars: aggressive deleveraging, valuation upside, and a potential debt refinancing. The firm projects leverage will decrease from approximately 10x in 2023 to 4.2x by 2027, driven by EBITDA growth to a forecasted $320 million. Currently, AVAH trades at 8.2x this 2027 EBITDA estimate, a notable discount to post-acute care peers that trade at low-double-digit multiples. Furthermore, the company's improved credit profile may enable a debt refinancing that could add $10-15 million to EPS and free cash flow, reinforcing the positive outlook shared by at least two other analysts who have recently revised their earnings estimates upward.

Key Decisions for Investors

• Given the significant Q2 earnings beat, strong stock momentum, and analyst upgrade to a $9.00 price target, investors may consider the current positive sentiment and operational outperformance as a strong bullish signal.
• The core long-term investment thesis hinges on execution of the deleveraging plan; investors should closely monitor future quarterly reports for continued EBITDA growth and progress on reducing leverage toward the 4.2x target.
• Investors should evaluate the valuation discount relative to peers and watch for news of a potential debt refinancing, as this could act as a significant near-term catalyst for both earnings per share and free cash flow.